Foresee Pharmaceuticals announces that a new U.S. patent which covers CAMCEVI® (leuprolide mesylate) and its labeled indication is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as "the Orange Book". On August 8, 2023, the United States Patent and Trademark Office (USPTO) issued U.S. patent No. 11,717,555 B2, under the title "Pharmaceutical Compositions Having a Selected Release Duration", which has extended the patent protection on CAMCEVI® to January 1, 2039.

The formulation patent covers not only CAMCEVI® but also Foresee's other LHRH products in development. The listing of the patent brings the total number of Orange Book-listed patents from three to four.